The clinic research of 6% hydroxyethyl starch 130/0.4 (Voluven) infusion on Chinese pediatric patients with congenital heart disease

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006963

Enrollment

Unknown

Registered

2015-08-23

Start date

2015-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric patients with congenital heart disease

Interventions

Two groups:hydmxyethyl starch 130/0.4

Eligibility

Sex/Gender

All

Age

2 Years to 18 Years

Inclusion criteria

Inclusion criteria: Forty-eight, ASA I-III CHD patients, aged <=12years old.

Exclusion criteria

Exclusion criteria: Preoperative liver, normal renal function, no allergy of hydroxyethyl starch.

Design outcomes

Primary

Measure	Time frame
Routine blood test;	—

Countries

China

Contacts

Public ContactJianzhong Zhang

factory_2001@sohu.com+86 18153529929

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026